Humana Reports Second Quarter 2024 Financial Results; Affirms Full Year Adjusted 2024 Financial Guidance

Rhea-AI Summary

Humana has reported its financial results for the second quarter of 2024. Key metrics include a GAAP EPS of $5.62 and an Adjusted EPS of $6.96. Year-to-date figures show a GAAP EPS of $11.74 and an Adjusted EPS of $14.19. Revenue for the quarter rose to $29.54 billion from $26.75 billion in 2Q23, while Adjusted Revenue increased to $29.38 billion from $25.73 billion.

However, the company revised its full-year GAAP EPS guidance to approximately $12.81 from $13.93, but maintained its Adjusted EPS guidance at $16.00. Additionally, Humana projected an increase in its individual Medicare Advantage membership growth by 75,000, anticipating a total growth of 225,000 members, or 4.2%, for 2024.

Operating cost ratio improved to 10.8% from 11.8% last year. The Insurance segment showed a benefits expense ratio of 89.5%, up from 86.8% in 2Q23. Operating cash flows decreased to $1.64 billion. The announcement included a Q&A session at 9 a.m. ET and updates on their Investor Relations page.

Positive

• 2Q24 revenue increased to $29.54B from $26.75B in 2Q23.
• Adjusted 2Q24 revenue rose to $29.38B from $25.73B.
• Operating cost ratio improved to 10.8% from 11.8% in 2Q23.
• Projected individual Medicare Advantage membership growth increased by 75,000, totaling 225,000 members or 4.2% for 2024.

Negative

• GAAP EPS guidance for FY 2024 revised down to $12.81 from $13.93.
• Benefits expense ratio for the Insurance segment increased to 89.5% from 86.8% in 2Q23.
• Operating cash flows decreased to $1.64B.

Financial Analyst

Humana's Q2 2024 results present a mixed picture for investors. While the company reported adjusted EPS of $6.96, beating expectations, this represents a 22.1% decline from Q2 2023. The decrease in earnings can be attributed to higher medical costs, with the benefits expense ratio increasing to 89.0% from 86.3% year-over-year.

On a positive note, Humana raised its 2024 individual Medicare Advantage membership growth forecast by 75,000 to approximately 225,000, indicating strong demand for its core products. This 4.2% projected growth in membership could drive future revenue increases.

However, the company revised its full-year 2024 GAAP EPS guidance downward to $12.81 from $13.93, while maintaining its adjusted EPS guidance of $16.00. This revision suggests ongoing challenges in managing medical costs and potential headwinds in the second half of the year.

Investors should closely monitor Humana's ability to control medical costs and improve its benefit ratio in the coming quarters. The company's success in growing its Medicare Advantage membership could provide a buffer against these cost pressures, but sustained profitability will depend on effective cost management strategies.

Healthcare Policy Expert

Humana's Q2 results reflect broader trends in the healthcare industry, particularly the challenges faced by insurers in managing rising medical costs. The increase in the benefits expense ratio to 89.0% is concerning and may be indicative of industry-wide inflationary pressures on healthcare services and utilization rates.

The company's focus on Medicare Advantage growth is strategically sound, given the aging U.S. population and the program's popularity. Humana's projected 4.2% growth in this segment outpaces overall Medicare Advantage market growth, suggesting effective marketing and competitive plan offerings.

However, the downward revision of GAAP EPS guidance while maintaining adjusted EPS guidance raises questions about the sustainability of Humana's earnings quality. Investors should scrutinize the nature and frequency of adjustments made to reconcile GAAP and non-GAAP figures.

Looking ahead, potential changes in healthcare policy, such as drug pricing reforms or adjustments to Medicare Advantage reimbursement rates, could significantly impact Humana's profitability. The company's ability to navigate these potential regulatory changes will be important for long-term success in the evolving healthcare landscape.

• Reports 2Q24 earnings per share (EPS) of $5.62 on a GAAP basis, Adjusted EPS of $6.96; reports YTD 2024 EPS of $11.74 on a GAAP basis, $14.19 on an Adjusted basis
• Revises FY 2024 EPS guidance to 'approximately $12.81' (previously 'approximately $13.93') on a GAAP basis, while affirming Adjusted EPS of 'approximately $16.00'; affirms FY 2024 Insurance segment benefit ratio of approximately 90 percent
• Raises 2024 individual Medicare Advantage annual membership growth by 75,000 to now anticipate annual growth of approximately 225,000, or 4.2 percent
• Publishes Letter from the CEO and prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 9:00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings

LOUISVILLE, Ky.--(BUSINESS WIRE)-- Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended June 30, 2024 (2Q24) versus the quarter ended June 30, 2023 (2Q23) and for the six months ended June 30, 2024 (YTD 2024) versus the six months ended June 30, 2023 (YTD 2023) as noted in the tables below.

Consolidated income before income taxes and equity in net earnings (pretax results) In millions	2Q24 (a)	2Q23 (a)	YTD 2024 (a)	YTD 2023 (a)
Generally Accepted Accounting Principles (GAAP)	$918	$1,262	$1,932	$2,876
Amortization associated with identifiable intangibles	15	16	31	34
Put/call valuation adjustments associated with the company's non-consolidating minority interest investments	68	53	199	107
Impact of exit of employer group commercial medical products business	59	45	60	(37)
Value creation initiatives	68	—	97	—
Transaction and integration costs	—	4	—	(48)
Accrued charge related to certain anticipated litigation expenses	—	90	—	90
Change in fair market value of publicly-traded equity securities	—	—	—	(1)
Adjusted (non-GAAP)	$1,128	$1,470	$2,319	$3,021

Diluted earnings per share (EPS)	2Q24 (a)	2Q23 (a)	YTD 2024 (a)	YTD 2023 (a)
GAAP	$5.62	$7.66	$11.74	$17.54
Amortization associated with identifiable intangibles	0.13	0.13	0.25	0.27
Put/call valuation adjustments associated with the company's non-consolidating minority interest investments	0.57	0.43	1.65	0.85
Impact of exit of employer group commercial medical products business	0.49	0.35	0.50	(0.30)
Value creation initiatives	0.56	—	0.80	—
Transaction and integration costs	—	0.03	—	(0.38)
Accrued charge related to certain anticipated litigation expenses	—	0.72	—	0.72
Change in fair market value of publicly-traded equity securities	—	—	—	(0.01)
Cumulative net tax impact of non-GAAP adjustments	(0.41)	(0.38)	(0.75)	(0.37)
Adjusted (non-GAAP)	$6.96	$8.94	$14.19	$18.32
Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations.

Please refer to the tables above, as well as the consolidated and segment highlight sections in the detailed earnings release for additional discussion of the factors impacting the year-over-comparisons.

In addition, a summary of key consolidated and segment statistics comparing 2Q24 to 2Q23 and YTD 2024 to YTD 2023 follows.

Humana Inc. Summary of Results ($ in millions, except per share amounts)	2Q24 (a)			2Q23 (a)			YTD 2024 (a)			YTD 2023 (a)
CONSOLIDATED
Revenues	$	29,540		$	26,747		$	59,151		$	53,489
Revenues - Adjusted (non-GAAP)	$	29,380		$	25,733		$	58,711		$	51,385
Pretax results	$	918		$	1,262		$	1,932		$	2,876
Pretax results - Adjusted (non-GAAP)	$	1,128		$	1,470		$	2,319		$	3,021
EPS	$	5.62		$	7.66		$	11.74		$	17.54
EPS - Adjusted (non-GAAP)	$	6.96		$	8.94		$	14.19		$	18.32
Benefits expense ratio		89.0	%		86.3	%		88.9	%		85.9	%
Benefits expense ratio - Adjusted (non-GAAP)		88.9	%		86.1	%		88.9	%		86.0	%
Operating cost ratio		10.8	%		11.8	%		10.6	%		11.5	%
Operating cost ratio - Adjusted (non-GAAP)		10.5	%		11.2	%		10.4	%		11.0	%
Operating cash flows							$	1,636		$	9,863
Operating cash flows - Adjusted (non-GAAP) (b)							$	1,636		$	2,861
Parent company cash and short term investments							$	1,256		$	1,109
Debt-to-total capitalization								43.6	%		41.0	%
Days in Claims Payable (DCP)		41.6			42.6
INSURANCE SEGMENT
Revenues	$	28,525		$	25,875		$	57,224		$	51,778
Revenues - Adjusted (non-GAAP)	$	28,365		$	24,861		$	56,784		$	49,675
Benefits expense ratio		89.5	%		86.8	%		89.4	%		86.4	%
Benefits expense ratio - Adjusted (non-GAAP)		89.4	%		86.6	%		89.4	%		86.5	%
Operating cost ratio		8.4	%		9.9	%		8.4	%		9.6	%
Operating cost ratio - Adjusted (non-GAAP)		8.4	%		9.2	%		8.3	%		9.1	%
Income from operations	$	763		$	1,031		$	1,661		$	2,358
Income from operations - Adjusted (non-GAAP)	$	826		$	1,172		$	1,730		$	2,422
CENTERWELL SEGMENT
Revenues	$	4,947		$	4,530		$	9,765		$	9,035
Operating cost ratio		92.0	%		92.6	%		92.5	%		92.1	%
Income from operations	$	338		$	287		$	620		$	617
Income from operations - Adjusted (non-GAAP) (c)	$	394		$	337		$	729		$	716
Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.

FY 2024 Earnings Guidance

Humana revised its GAAP EPS guidance for the year ending December 31, 2024 (FY 2024) to approximately $12.81 from approximately $13.93, while affirming its Adjusted EPS guidance of approximately $16.00.

Diluted earnings per share	FY 2024 Guidance
GAAP	approximately $12.81
Amortization of identifiable intangibles	0.50
Put/call valuation adjustments associated with the company's non-consolidating minority interest investments (d)	1.65
Impact of exit of employer group commercial medical products business	1.21
Value creation initiatives (d)	0.80
Cumulative net tax impact of non-GAAP adjustments	(0.97)
Adjusted (non-GAAP) – FY 2024 projected	approximately $16.00
Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations.

Detailed Press Release

Humana’s full earnings press release, including the statistical pages, has been posted to the company’s Investor Relations site and may be accessed at https://humana.gcs-web.com/ or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at www.sec.gov or on the company’s website).

Conference Call

Humana will host a live question and answer session for analysts at 9:00 a.m. Eastern time today to discuss its financial results for the quarter and the company’s expectations for future earnings. In advance of the question and answer session, Humana will post a Letter from the CEO and prepared management remarks to the Quarterly Results section of its Investor Relations page (https://humana.gcs-web.com/financial-information/quarterly-results).

To participate via phone, please register in advance at this link - https://register.vevent.com/register/BI4837b56336d1453fb10a8fdaada5e1c0.

Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID that can be used to access the call.

A webcast of the 2Q24 earnings call may also be accessed via Humana’s Investor Relations page at humana.com. The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call.

For those unable to participate in the live event, the archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page (https://humana.gcs-web.com/events-and-presentations), approximately two hours following the live webcast.

Footnotes

The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company’s core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent and uniform indicators of the company’s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. All financial measures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.

(a) For the periods covered in this earnings press release, the following items are excluded from the non-GAAP financial measures described above, as applicable:

• Amortization associated with identifiable intangibles - Since amortization varies based on the size and timing of acquisition activity, management believes this exclusion provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments income from operations. The table below discloses respective period amortization expense for each segment:

	2Q24	2Q23	YTD 2024	YTD 2023
Insurance segment	$4	$6	$9	$11
CenterWell segment	$11	$10	$22	$23

• Put/call valuation adjustments associated with the company’s non-consolidating minority interest investments - These amounts are the result of fair value measurements associated with the company's Primary Care Organization strategic partnership and are unrelated to the company's core business operations. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and EPS.
• Impact of exit of employer group commercial medical products business - These amounts relate to activity from the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results, EPS, consolidated revenues, consolidated benefit ratio, consolidated operating cost ratio, Insurance segment revenues, Insurance segment benefit ratio, Insurance segment operating cost ratio, and Insurance segment income from operations.
• Value creation initiatives - These charges relate to the company's ongoing initiative to drive additional value for the enterprise through cost saving, productivity initiatives, and value creation from previous investments, and primarily consist of asset impairment and severance charges. For 2Q24 and YTD 2024, GAAP measures affected in this release include consolidated pretax results, EPS, and the consolidated operating cost ratio.
• Transaction and integration costs - The transaction and integration costs primarily relate to the acquisition of Kindred at Home in 2021 and the subsequent divestiture of Gentiva (formerly Kindred) Hospice in 2022. For 2Q23 and YTD 2023, GAAP measures affected include consolidated pretax results, EPS, and the consolidated operating cost ratio.
• Accrued charge related to certain anticipated litigation expenses - This charge relates to certain anticipated expenses the company has accrued in connection with a legal matter. For 2Q23 and YTD 2023, GAAP measures affected include consolidated pretax results, EPS, the consolidated and Insurance segment operating cost ratios, and Insurance segment income from operations.
• Change in fair market value of publicly-traded equity securities - These gains and losses are a result of market and economic conditions that are unrelated to the company's core business operations. For YTD 2023, GAAP measures affected include consolidated pretax results, EPS, and consolidated revenues (specifically investment income).
• Cumulative net tax impact of non-GAAP adjustments - This adjustment represents the cumulative net impact of the corresponding tax benefit or expense related to the aforementioned items excluded from the applicable GAAP measures. For all periods presented in this earnings release, EPS is the sole GAAP measure affected.

In addition to the reconciliations shown on page 2 of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release:

Revenues

Revenues - CONSOLIDATED (in millions)		2Q24			2Q23		YTD 2024			YTD 2023
GAAP	$	29,540		$	26,747		$	59,151		$	53,489
Change in fair market value of publicly-traded equity securities		—			—			—			(1	)
Impact of exit of employer group commercial medical products business		(160	)		(1,014	)		(440	)		(2,103	)
Adjusted (non-GAAP)	$	29,380		$	25,733		$	58,711		$	51,385

Revenues - INSURANCE SEGMENT (in millions)	2Q24			2Q23			YTD 2024			YTD 2023
GAAP	$	28,525		$	25,875		$	57,224		$	51,778
Impact of exit of employer group commercial medical products business		(160	)		(1,014	)		(440	)		(2,103	)
Adjusted (non-GAAP)	$	28,365		$	24,861		$	56,784		$	49,675

Benefit Ratio

Benefit ratio - CONSOLIDATED	2Q24		2Q23		YTD 2024		YTD 2023
GAAP	89.0	%	86.3	%	88.9	%	85.9	%
Impact of exit of employer group commercial medical products business	(0.1	)%	(0.2	)%	—	%	0.1	%
Adjusted (non-GAAP)	88.9	%	86.1	%	88.9	%	86.0	%

Benefit ratio - INSURANCE SEGMENT	2Q24		2Q23		YTD 2024		YTD 2023
GAAP	89.5	%	86.8	%	89.4	%	86.4	%
Impact of exit of employer group commercial medical products business	(0.1	)%	(0.2	)%	—	%	0.1	%
Adjusted (non-GAAP)	89.4	%	86.6	%	89.4	%	86.5	%

Operating Cost Ratio

Operating cost ratio - CONSOLIDATED	2Q24		2Q23		YTD 2024		YTD 2023
GAAP	10.8	%	11.8	%	10.6	%	11.5	%
Impact of exit of employer group commercial medical products business	(0.1	)%	(0.2	)%	(0.1	)%	(0.3	)%
Value creation initiatives	(0.2	)%	—	%	(0.1	)%	—	%
Accrued charge related to certain anticipated litigation expenses	—	%	(0.4	)%	—	%	(0.2	)%
Adjusted (non-GAAP)	10.5	%	11.2	%	10.4	%	11.0	%

Operating cost ratio - INSURANCE SEGMENT	2Q24		2Q23		YTD 2024		YTD 2023
GAAP	8.4	%	9.9	%	8.4	%	9.6	%
Impact of exit of employer group commercial medical products business	—	%	(0.3	)%	(0.1	)%	(0.3	)%
Accrued charge related to certain anticipated litigation expenses	—	%	(0.4	)%	—	%	(0.2	)%
Adjusted (non-GAAP)	8.4	%	9.2	%	8.3	%	9.1	%

Income from Operations

Income from operations - INSURANCE SEGMENT	2Q24		2Q23		YTD 2024		YTD 2023
GAAP	$	763	$	1,031	$	1,661	$	2,358
Amortization associated with identifiable intangibles		4		6		9		11
Impact of exit of employer group commercial medical products business		59		45		60		(37	)
Accrued charge related to certain anticipated litigation expenses		—		90		—		90
Adjusted (non-GAAP)	$	826	$	1,172	$	1,730	$	2,422

(b) Generally, when the first day of a month falls on a weekend or holiday, with the exception of January 1 (New Year's Day), the company receives its monthly Medicare premium payment from CMS on the last business day of the previous month. On a GAAP basis, this can result in certain quarterly cash flows from operations including more or less than three monthly payments. Consequently, when this occurs, the company reports Adjusted cash flows from operations to reflect three payments in each quarter to match the related expenses.

Net cash from operating activities (in millions)	YTD 2024		YTD 2023
GAAP	$	1,636	$	9,863
Timing of premium payment from CMS		—		(7,002	)
Adjusted (non-GAAP)	$	1,636	$	2,861

(c) The CenterWell segment Adjusted income from operations includes an adjustment to add back depreciation and amortization expense to the segment's GAAP income from operations since such an adjustment is commonly utilized for valuation purposes within the healthcare delivery industry.

Income from operations - CENTERWELL SEGMENT (in millions)	2Q24		2Q23		YTD 2024		YTD 2023
GAAP	$	338	$	287	$	620	$	617
Depreciation and amortization expense		56		50		109		99
Adjusted (non-GAAP)	$	394	$	337	$	729	$	716

(d) FY 2024 projected Adjusted results exclude the future impact of items that cannot be estimated at this time; YTD 2024 amounts shown.

Cautionary Statement

This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana’s executive officers, the words or phrases like “expects,” “believes,” “anticipates,” “assumes,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the company’s SEC filings, a summary of which includes but is not limited to the following:

• If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana’s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient.
• If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the company’s business may be materially adversely affected. In addition, there can be no assurances that the company will be successful in maintaining or improving its Star ratings in future years.
• If Humana, or the third-party service providers on which it relies, fails to properly maintain the integrity of its data, to strategically maintain existing or implement new information systems, to protect Humana’s proprietary rights to its systems, or to defend against cyber-security attacks, contain such attacks when they occur, or prevent other privacy or data security incidents that result in security breaches that disrupt the company's operations or in the unintentional dissemination of sensitive personal information or proprietary or confidential information, the company’s business may be materially adversely affected.
• Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company’s cost of doing business.
• As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts; governmental audits and investigations; potential inadequacy of government determined payment rates; potential restrictions on profitability, including by comparison of profitability of the company’s Medicare Advantage business to non-Medicare Advantage business; or other changes in the governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a "Fee for Service Adjuster" could have a material adverse effect on the company's operating results, financial position and cash flows.
• Humana's business activities are subject to substantial government regulation. New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company's cost of doing business and have a material adverse effect on Humana’s results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company’s ability to expand into new markets, increasing the company’s medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company’s Medicare payment rates and increasing the company’s expenses associated with a non-deductible health insurance industry fee and other assessments); the company’s financial position (including the company’s ability to maintain the value of its goodwill); and the company’s cash flows.
• Humana’s failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company’s results of operations, financial position, and cash flows.
• If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company’s business may be adversely affected.
• Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company’s success, and its failure to do so could adversely affect the Company’s businesses, operating results and/or future performance.
• Humana’s pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses.
• Changes in the prescription drug industry pricing benchmarks may adversely affect Humana’s financial performance.
• Humana’s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.
• Downgrades in Humana’s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.
• Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio.

In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance:

• Form 10-K for the year ended December 31, 2023;

• Form 10-Q for the quarter ended March 31, 2024; and

• Form 8-Ks filed during 2024.

About Humana

Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731887420/en/

Lisa Stoner

Humana Investor Relations

(502) 580-2652

e-mail: LStamper@humana.com

Mark Taylor

Humana Corporate Communications

(317) 753-0345

e-mail: MTaylor108@humana.com

Source: Humana Inc.

FAQ

What were Humana's earnings per share (EPS) for 2Q24?

Humana reported a GAAP EPS of $5.62 and an Adjusted EPS of $6.96 for 2Q24.

Did Humana revise its full-year 2024 GAAP EPS guidance?

Yes, Humana revised its full-year 2024 GAAP EPS guidance to approximately $12.81 from $13.93.

What is Humana's projected Adjusted EPS for FY 2024?

Humana affirmed its projected Adjusted EPS of approximately $16.00 for FY 2024.

How much did Humana's revenue grow in 2Q24?

Humana's revenue grew to $29.54 billion in 2Q24, up from $26.75 billion in 2Q23.

What is the projected growth in Humana's individual Medicare Advantage membership for 2024?

Humana projects an increase in individual Medicare Advantage membership by 75,000, bringing the total anticipated growth to 225,000 members or 4.2% for 2024.